Competitive research grant to evaluate the clinical effectiveness of ATM-AVI (aztreonam–avibactam) in patients with carbapenem-resistant Enterobacterales (CRE), including MBL-producing CRE, across hospitals in mainland China and Hong Kong.
Eligibility Criteria:
-
Principal Investigator and institution must be based in mainland China or Hong Kong.
-
Only organizations are eligible to receive funding (not individuals or independent practice groups).
-
PI must hold an MD, PhD, or equivalent medical/clinical research degree and be employed or contracted by the applying institution.
-
Institutions must be able to receive award funding directly from Pfizer Investment Co., Ltd. or Pfizer Corporation Hong Kong Limited.
Funding Details:
-
Up to USD 35,000 per project.
-
Total available budget: USD 413,000.
-
Project duration: 12 to 36 months.
Deadline:
-
Application Due: October 15, 2025 (23:59 EST).
-
Award Notification: January 15, 2026.
-
Project Start: May 16, 2026 – End: May 15, 2029.
Where To Go For Further Information:
-
Submit online via Pfizer Research Grants portal.